Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Interferon-free treatment regimen for Hepatitis C virus infection

This week's New England Journal of Medicine investigates the use of oral combination antiviral therapy for Hepatitis C.

News image

There is a need for interferon-free treatment regimens for hepatitis C virus infection.

Dr Fred Poordad and colleagues from Texas, USA evaluated ABT-450, a potent hepatitis C virus NS3 protease inhibitor, combined with low-dose ritonavir, in addition to ABT-333, a nonnucleoside NS5B polymerase inhibitor, and ribavirin, for the treatment of hepatitis C virus infection.

The team of doctors conducted a 12-week, phase 2a, open-label study involving patients who had hepatitis C virus genotype 1 infection without cirrhosis.

All patients received ABT-333 and ribavirin, and one of two daily doses of ABT-450/r.

Groups 1 and 2 included previously untreated patients.

Group 1 received 250 mg of ABT-450 and 100 mg of ritonavir, and Group 2 received 150 mg and 100 mg, respectively.

Sustained virologic response 12 weeks after the end of treatment was achieved in 95% of Group 1
New England Journal of Medicine

Group 3, which included patients who had had a null or partial response to previous therapy with peginterferon and ribavirin, received daily doses of 150 mg of ABT-450 and 100 mg of ritonavir.

The team's primary end point was an undetectable level of hepatitis C virus RNA from week 4 through week 12.

A total of 17 of the 19 patients in Group 1, and 11 of the 14 in Group 2 had an extended rapid virologic response.

There was a sustained virologic response 12 weeks after the end of treatment was achieved in 95% and 93% of the patients, respectively.

The researchers observed that in Group 3, 10 of 17 patients had an extended rapid virologic response, 8 had a sustained virologic response 12 weeks after therapy, 6 patients had virologic breakthrough, and 3 had a relapse.

The team noted that adverse events included abnormalities in liver-function tests, fatigue, nausea, headache, dizziness, insomnia, pruritus, rash, and vomiting.

Dr Poordad's team concludes, "This preliminary study suggests that 12 weeks of therapy with a combination of a protease inhibitor, a nonnucleoside polymerase inhibitor, and ribavirin may be effective for treatment of HCV genotype 1 infection."

N Engl J Med 2013; 368:45-53January 3
10 January 2013

Go to top of page Email this page Email this page to a colleague

 22 December 2014

Advanced search
 22 December 2014 
Happy holidays!
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 18 December 2014 
Assessment of Crohn's disease activity
 18 December 2014 
Vitamin D and sustained virologic response in HCV
 18 December 2014 
Factor for treatment in IBS
 17 December 2014 
Non-invasive measures of fatty liver
 17 December 2014 
Remission from hepatic encephalopathy with rifaximin
 17 December 2014 
Colonic adenoma recurrence after endoscopic resection
 16 December 2014 
Screening esophagus during routine US
 16 December 2014 
Therapeutic targets in IBD
 16 December 2014 
Diagnostic tool for dysplasia in Barrett's
 15 December 2014 
Esophageal adenocarcinoma and Barrett's
 15 December 2014 
Outcomes of mildly abnormal liver function tests
 15 December 2014 
Food allergy and food intolerances
 12 December 2014 
Hospital readmission after colorectal resection
 12 December 2014 
Detecting intestingal damage in Crohn's
 12 December 2014 
SSRIs for noncardiac chest pain
 11 December 2014 
Hep C and post-liver transplant diabetes
 11 December 2014 
Antiviral therapy and post-hepatectomy survival
 11 December 2014 
Barrett’s risk factors in African Americans vs Non-Hispanic Whites
 10 December 2014 
Prompt endoscopy for uninvestigated dyspepsia
 10 December 2014 
Microbiota composition on gluten-free diet in celiac disease
 10 December 2014 
Utilization of health care resources in ileostomy patients
 09 December 2014 
Diverticular disease and irritable bowel syndrome
 09 December 2014 
Management of acute colonic diverticulitis
 09 December 2014 
Food intolerance
 08 December 2014 
Portal vein obstruction
 08 December 2014 
Readmission after restorative proctocolectomy with IPAA
 08 December 2014 
Metachronous colorectal cancer
 05 December 2014 
Esophageal cancer in Veterans with Barrett’s esophagus
 05 December 2014 
Clinical outcome in pediatric Crohn's
 05 December 2014 
Hepatocellular carcinoma surveillance survey
 04 December 2014 
Diagnosis of NAFLD and NASH
 04 December 2014 
Ethnic disparities in gastric cancer
 04 December 2014 
Gilbert's syndrome and respiratory health
 03 December 2014 
Unmet treatment needs of GERD
 03 December 2014 
Finding sessile serrated adenomas during colonoscopy
 03 December 2014 
Antibiotics in acute uncomplicated diverticulitis
 02 December 2014 
Vit D and sustained virologic response in Hep C
 02 December 2014 
Severe esophagitis and upper GI bleeding
 02 December 2014 
Critical illness in patients with IBD
 01 December 2014 
Algorithms for the diagnosis of Lynch syndrome
 01 December 2014 
Differentiates inflammatory from functional intestinal disorders
 01 December 2014 
Racial disparities in colorectal cancer survival
 28 November 2014 
C. diff and pediatric IBD
 28 November 2014 
Fruit and vegetable consumption and esophageal cancer
 28 November 2014 
IBD and students' adjustment to college
 27 November 2014 
Prediction of functional GI disorders later in life
 27 November 2014 
Differences in the incidence of esophageal adenocarcinoma
 27 November 2014 
End points of outcomes in primary biliary cirrhosis
 26 November 2014 
Detection of gastric precancerous conditions
 26 November 2014 
Vegetables and garlic and colorectal cancer risk
 26 November 2014 
Fertility in women with celiac disease
 25 November 2014 
Esophagogastric junction of children with GERD
 25 November 2014 
Symptom activity index for eosinophilic esophagitis
 25 November 2014 
Placebo response rate in fistulizing Crohn's
 24 November 2014 
Nasoenteric tube feeding in acute pancreatitis
 24 November 2014 
Corticosteroids and infections in elderly-onset IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us